Dermatology News

Patients with rheumatoid arthritis, gout, polydermatomyositis, vasculitis and those with multiple rheumatic diseases were at greatest risk for breakthrough COVID-19 infection, despite full or partial vaccination vs. those without rheumatic disease.

While there is a cross-section of drugs that are FDA-approved for the treatment of axial spondyloarthritis, clinicians and researchers continue to struggle with axial psoriatic arthritis, according to a presenter at ACR Convergence 2021.

Therapeutic drug monitoring, in which serum levels are regularly checked to adjust dose and intervals, is more effective at controlling disease than standard therapy with infliximab, according to data presented at ACR Convergence 2021.

The use of vitamin D3 or omega-3 fatty acid supplements over a 5-year period may reduce the incidence of autoimmune disease in older adults by 25% to 30%, according to data presented at ACR Convergence 2021.

Risankizumab provides statistically greater improvements in signs and symptoms relative to placebo, and is well tolerated among patients with psoriatic arthritis, according to data presented at ACR Convergence 2021.

Among patients treated with TNF inhibitors, the risk for serious infection was “significantly lower” in those with psoriatic arthritis compared with rheumatoid arthritis, according to data published in the Annals of the Rheumatic Diseases.

Halloween costumes for kids, adolescents and adults can be fun and creative, but makeup and masks can often cause irritation that could lead to acne, dermatitis or other skin problems.

Physical activity can lead to improved quality of life and self-reported function in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis, according to data published in Arthritis Care & Research.

A 2-month-old male presented virtually to his primary provider with gradually worsening red skin and fussiness, which was first noted a few weeks earlier.

Treat-to-target tapering of TNF inhibitors in patients with psoriatic arthritis or axial spondyloarthritis does not result in any negative impact on disease activity, compared with the full dose, according to data published in Rheumatology.